

# PROVIDER Update



CONTRACTUAL | JANUARY 4, 2024 | UPDATE 24-020m | 3 PAGES

## Medication Trend Updates and Formulary Changes – 1st Quarter 2024

### Review formulary changes and medication safety issues

Stay up to date with information about:

- FDA updated boxed warnings to improve safe use of prescription stimulants to treat attention-deficit/hyperactivity disorder (ADHD).
- Changes to the Health Net\*, on behalf of Community Health Plan of Imperial Valley), commercial Formulary, Medi-Cal Preferred Drug List (PDL) and Medicare Part D Formulary for the first quarter of 2024.

#### FDA updated boxed warnings to improve safe use of prescription stimulants to treat ADHD

In an effort to address the harms of misuse and abuse of stimulants prescribed to treat conditions such as ADHD, the U.S. Food and Drug Administration updated warnings on the labels of prescription stimulants.

The updated boxed warnings in the prescribing information for the entire class of prescription stimulants will include information about the risks of abuse, misuse, addiction, and overdose, as well as language advising physicians to monitor patients closely for these risks. Commonly prescribed drugs in this class include amphetamine/dextroamphetamine (Adderall), methylphenidate (Concerta), dextroamphetamine (Dexedrine), lisdexamfetamine dimesylate (Vyvanse), and methylphenidate (Ritalin). These medications are indicated for the management of ADHD as well as eating disorders and narcolepsy.

This labeling update was based on a review of medical literature (between January 2006 and May 2020) on nonmedical use of prescription stimulants. Family members and friends were the most common source of prescription stimulants for nonmedical use. According to the literature, use of prescription stimulants by individuals who were not prescribed these medications has been associated with a higher risk of developing substance use disorder and addiction.

The new labeling advises health care professionals to monitor patients for obvious signs of abuse or addiction. Patients should be counseled not to share their prescribed stimulants with anyone else. Health care providers are encouraged to educate both patients and families about the serious risks of these drugs as well as proper storage and disposal of any unused medicine. In addition, careful records

#### THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups

#### PROVIDER SERVICES

**CHPIV Medi-Cal (including ECM and CS providers) – 833-236-4141**

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com)

Community Health Plan of Imperial Valley ("CHPIV") is the Local Health Authority (LHA) in Imperial County, providing services to Medi-Cal enrollees in Imperial County. CHPIV contracts with Health Net Community Solutions, Inc. to arrange health care services to CHPIV members. \*Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at [provider.communications@healthnet.com](mailto:provider.communications@healthnet.com) indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

---

should be kept that indicate the quantity, frequency, and renewal requests for these medications.

### **Drug benefit changes**

The Pharmacy and Therapeutics (P&T) Committee includes practicing physicians, pharmacists and other health care professionals. Each quarter, the P&T Committee reviews medications on the Formulary for commercial members, the PDL for Medi-Cal members, and the Medicare Part D Formulary for Medicare members to determine which medications remain on the same tier and which are moved. A table listing some recent changes is available on page 3. The list contains brand-name prescription medications, status, other medication choices, and comments for the first quarter of 2024.

The complete lists of the commercial Formularies, Medi-Cal PDLs and Medicare Part D Formularies are available on the Plan provider website.

### **Pharmacy help line**

For more information regarding changes to the Medi-Cal medical benefit drugs, contact the proper pharmacy phone number listed.

<b>Product</b>	<b>Phone number</b>	<b>Fax number</b>
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-675-6110	833-953-3436

### **Additional information**

Providers are encouraged to access the provider portal online at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update), contact Community Health Plan of Imperial Valley at 833-236-4141.

## Changes to the Community Health Plan of Imperial Valley Medi-Cal drug benefits

Medication	Status	Formulary alternative(s)	Comments
<b>Oral preparation</b>			
Zurzuvae™ (zuranolone) capsule	Carved out to State		Treatment of postpartum depression in adults
<b>Injectable preparation</b>			
Adalimumab-adaz injection by Sandoz	Carved out to State		Now preferred for commercial line of business; biosimilar to Humira.
Amjevita™ (adalimumab-atto) injection	Carved out to State		Nonpreferred for commercial line of business; biosimilar to Humira.
Elevidys™ (delandistrogene moxparvovec-rokl) suspension for intravenous infusion	Medical Benefit <sup>1</sup>		Treatment of ambulatory pediatric patients aged four through five years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.
Hadlima (adalimumab-bwvd) injection	Carved out to State		Now preferred for commercial line of business; biosimilar to Humira.
Roctavian™ (valoctocogene - roxaparvovec-rvox) suspension for intravenous infusion	Medical Benefit <sup>1</sup>		Treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.
<b>Topical preparation</b>			
Vyjuvek™ (beremagene geperpavec-svdt) suspension for topical application	Carved out to State		Treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB) with mutations(s) in the collagen type VII alpha 1 chain (COL7A1) gene.

Note: The information above is subject to change. Please refer to Health Net website for the most up-to-date formulary status.

<sup>1</sup>Prior authorization (PA) is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.